Multipharmacophore strategy in medicinal chemistry for the design of drugs for the treatment of Alzheimer’s and some other neurodegenerative diseases
Authors:
- 1 January 2023
- journal article
- review article
- Published by Springer Nature in Russian Chemical Bulletin
- Vol. 72 (1) , 130-147
Abstract
No abstract availableKeywords
This publication has 50 references indexed in Scilit:
- Conjugates of γ-Carbolines and Phenothiazine as new selective inhibitors of butyrylcholinesterase and blockers of NMDA receptors for Alzheimer DiseaseScientific Reports, 2015
- 3-Hydroxy-4-pyridinone derivatives designed for fluorescence studies to determine interaction with amyloid protein as well as cell permeabilityBioorganic & Medicinal Chemistry Letters, 2015
- Neuroprotective efficacy of aminopropyl carbazoles in a mouse model of amyotrophic lateral sclerosisProceedings of the National Academy of Sciences, 2012
- Overexpression of human wild-type FUS causes progressive motor neuron degeneration in an age- and dose-dependent fashionActa Neuropathologica, 2012
- Development of Proneurogenic, Neuroprotective Small MoleculesJournal of the American Chemical Society, 2011
- Discovery of a Proneurogenic, Neuroprotective ChemicalCell, 2010
- Methylene blue and dimebon inhibit aggregation of TDP‐43 in cellular modelsFEBS Letters, 2009
- Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled studyThe Lancet, 2008
- Amyloid–cholinesterase interactionsThe FEBS Journal, 2008
- Structural Basis for Understanding Structure−Activity Relationships for the Glutamate Binding Site of the NMDA Receptor.Journal of Medicinal Chemistry, 2002